Application of a quality management system - Quality in blood and tissue establishments and hospital blood banks - Chapter 2
2.5.1: Blood Establishments
Blood Establishments are required under Directive 2005/62/EC to implement European Community (EC) standards and specifications relating to a quality system for Blood Establishments, taking fully into account the principles of Good Manufacturing Practice (GMP).
Commission Directive (EU) 2016/1214 of 25 July 2016 amended Directive 2005/62/EC as regards quality system standards and specifications for blood establishments. This replaced article 2 with the requirement that systems should be developed taking into account the Good Practice Guidelines jointly developed by the Commission and the European Directorate for the Quality of Medicines and Healthcare of the Council of Europe and published by the Council of Europe.
The approach we have taken in this chapter is to outline the requirements of a quality management system in the context of the collection, processing, testing, storage and distribution of blood and blood components and tissues.
In addition, Blood Establishments should ensure they are compliant with the specific standards identified within the Blood Safety and Quality Regulations 2005 (BSQR) and other relevant standards and guidelines. These elements of the quality management system can be adapted to support other activities that a Blood Establishment may undertake, such as diagnostic testing and reagent production.
Blood Establishments are required to obtain a Blood Establishment Authorisation from MHRA before operating and to ensure that it is maintained through inspections scheduled every 2 years.
2.5.2: Hospital blood banks
Hospital blood banks are required to comply with the elements of the quality system outlined below relevant to their activities (see chapter 2.6). In addition, they must:
- Maintain donor to recipient traceability. Specifically, BSQR Regulation 9 (1)(e) requires hospital transfusion laboratories to 'maintain, for not less than 30 years, the data needed to ensure full traceability of blood and blood components, from the point of receipt of the blood or blood component by the hospital blood bank'.
- Undertake mandatory reporting of serious adverse events and serious adverse reactions related to transfusion to the Competent Authority. Specifically, BSQR Regulation 12B and Directive 2005/62 Annex, section 9.2 require that there are procedures in place for quality assurance within the transfusion laboratory for the reporting of Serious Adverse Events (SAEs) and Serious Adverse Reactions (SARs).
- Complete an annual form, the Blood Compliance Report, developed by the MHRA, in which the laboratory indicates its compliance with the regulations. The form is reviewed by the Inspectorate division of the MHRA and those laboratories where there is deemed non-compliance are inspected as 'for cause' inspections. There may also be some control inspections undertaken to verify the use of the Blood Compliance Report and its completion.
- Establish their bona fides with the supplying Blood Establishment and sign a service level agreement between both parties to outline how compliance will be achieved. This must be done before a hospital blood bank can operate.
2.5.3: Tissue and cell establishments
These establishments should also operate a quality system that reflects the requirements in chapter 2.6.
The Tissues and Cells Directives are not as explicit on the requirements of a quality management system as the Blood Safety and Quality Directives and a quality system in the context of the Tissues and Cells Directives consists of the following elements: the organisational structure, defined responsibilities, procedures, processes, and resources for implementing quality management, and includes all activities which contribute to quality, directly or indirectly.
Experience has shown that the elements described in chapter 2.6 are effective in maintaining quality and safety in the procurement and supply of tissues and cells.